|Bid||93.61 x 800|
|Ask||93.75 x 100|
|Day's Range||92.78 - 95.10|
|52 Week Range||75.81 - 106.74|
|Beta (3Y Monthly)||1.71|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||121.67|
Jazz Pharmaceuticals generated revenues of $469.4 million in the third quarter, which reflects ~14% YoY (year-over-year) growth. Jazz Pharmaceuticals’ net revenues over the first nine months of 2018 were $1.4 billion—compared to $1.2 billion in the same period in 2017, which reflects ~20% YoY growth.
SAN RAFAEL, Calif., Nov. 12, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) today announced the debut of the Broadway-style 'Hemophilia: The Musical,' a first-of-its-kind theatrical production featuring 25 students affected by a bleeding disorder. A recording of the six-song performance is now available at BreakingThroughHemophilia.com. "'Hemophilia: The Musical' was a defining moment for many of the young adults who participated," said Patrick James Lynch, Believe Limited CEO and Breaking Through! Musical Theater Intensive director.
- Credit Suisse 27th Annual Credit Suisse Healthcare Conference on November 13 in Scottsdale, AZ - Evercore ISI HealthConX Conference on November 28 in Boston SAN RAFAEL, Calif. , Nov. 8, 2018 /PRNewswire/ ...
Mergers and acquisitions have been proceeding at a torrid pace, and the health care sector may be an especially active area for future consolidation. In the first half of 2018, the value of M&A deals hit all-time records both worldwide and in the U.S., up by 64% and 79%, respectively, from the first half of 2017, per data from Thomson Reuters cited by Axios.com. Per Business Insider, these are the top 10 takeover candidates that Morgan Stanley sees in the health care sector: IQVIA Holdings Inc. ( IQV), BioMarin Pharmaceutical Inc. ( BMRN), Seattle Genetics Inc. ( SGEN), DaVita Inc. ( DVA), Universal Health Services Inc. ( UHS), Dexcom Inc. ( DXCM), Neurocrine Biosciences Inc. ( NBIX), Perrigo Co. PLC ( PRGO), Nektar Therapeutics ( NKTR), and Sarepta Therapeutics Inc. ( SRPT).
SAN RAFAEL, Calif., Nov. 7, 2018 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (BMRN) updated the investment community on the Company's research and development portfolio, which is focused on innovative therapies to treat rare and ultra-rare diseases. BioMarin announced today that the Phase 3 study of vosoritide in children is now fully enrolled and top line results are planned for the end of 2019. BioMarin has also initiated a global Phase 2 study in infants and young children up to age 5 with achondroplasia. See "About Vosoritide Phase 3 Study" below for more information on this study.
Key Research & Development Pipeline Products and Data to be Presented, Including: - Vosoritide for the Treatment of Achondroplasia 42-Month Data Update - Gene Therapy Product for the Treatment of Phenylketonuria ...
Incyte (INCY) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for revenue but missed estimates for EPS. It reported EPS of $0.14 on revenues of $449.68 million in the third quarter of 2018, compared to estimates for EPS of $0.40 on revenues of $449.20 million.
Allergan (AGN) released its Q3 2018 earnings today. The company beat Wall Street analysts’ estimates for EPS and revenues, and it reported non-GAAP EPS of $4.25 on revenues of $3.91 billion, compared to estimates for EPS of $4.03 on revenues of $3.88 billion during the third quarter of 2018.
NEW YORK, Oct. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Shire (SHPG) is a biotechnology company focused on discovering, developing, and commercializing specialty medicines to treat rare diseases and other specialized conditions. Shire is set to release its third quarter of 2018 earnings on November 1. Wall Street analysts estimate EPS of $3.58 on revenues of $3.82 billion.
Wall Street analysts estimate Incyte’s (INCY) revenues will increase by ~17.7% to $449.2 million during the third quarter of 2018 compared to revenues of $381.5 million during the third quarter of 2017. Also, the earnings per share are estimated to be $0.40 for the third quarter of 2018 as compared to earnings per share of $0.08 for the third quarter of 2017. Incyte stock has fallen nearly 46.6% over the last 12 months and decreased by ~35.7% in 2018 year-to-date.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Oct. 26) Endocyte, Inc. (NASDAQ: ECYT ) Imprimis Pharmaceuticals ...
Sarepta Therapeutics (SRPT) released its third-quarter 2018 results on October 24. Its net loss per share was $1.15 in the third quarter of 2018 as compared with net loss per share of $0.78 in the third quarter of 2017.
On a per-share basis, the San Rafael, California-based company said it had a loss of 7 cents. Earnings, adjusted for stock option expense, came to 14 cents per share. The results topped Wall Street expectations. ...
- First Nine Months of 2018 Total Revenues Grow 19% Year-over-year to $1.14 Billion - 124 Commercial Patients Receiving Treatment with Palynziq in First Full Quarter since U.S. Approval - Vosoritide 42-Month ...
Analysts are estimating that Allergan’s (AGN) third-quarter revenues will decrease 3.8% to $3.88 billion. Allergan has classified its business operations into three business segments: US Specialized Therapeutics US General Medicine International
Microsoft's median employee pay is high, even by Silicon Valley standards, but not quite as high as the typical worker's paycheck at Facebook, Google parent Alphabet, Netflix, or even smaller software companies like Box.
The SPDR Biotech ETF ( XBI) had been up 18% for 2018 at the start of September. Since then the Biotech ETF has given up nearly all of its gains and is now up less than 1% on the year. But not all biotechs have been poor performers during this time, and some may be poised to gain 15% or more in the final few weeks of 2018. The stock reached an intraday high of $23.50 on October 18, and should the stock be able to rise above technical resistance at $24, it could be on its way to $27.20. Should the stock rise above technical resistance at $45.25, the shares could increase to roughly $50.
Biotech stocks are staging a rebound following the losses incurred in the week ended Oct. 12 amid catalysts that include the third-quarter earnings season and presentations at the European Society of Medical ...